http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102816782-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fb38ebd40c70e97cc5f1519c6699162 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2012-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d321d18620a6278ae7ac3709b40fc77a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9e975901897fa2069c2f7bc1486d54d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_681a2d9771fe3eb313abf993af5a2d87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4730038d4a3d9ffe39466e4ea15eca2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7711267522e30903e01acde57567819f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d33c9f669d6432a9a6476a4b950be5c2 |
| publicationDate | 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102816782-B |
| titleOfInvention | TCR Valpha13:Zeta-IRES-Vbeta21:Zeta recombinant plasmid, its construction method and application thereof |
| abstract | The invention belongs to the technical field of anti-tumor immunity in hematologic tumor and especially relates to a chronic granulocytic leukemia related antigen specific TCR Zeta chimeric TCR gene related TCR Valpha13:Zeta-IRES-Vbeta21:Zeta recombinant plasmid, its construction method and an application thereof. The recombinant plasmid is obtained by respectively constructing TCR Valpha13:Zeta gene as shown in SEQ ID No.1 and TCRVbeta21:Zeta gene as shown in SEQ ID No.2 in multiple cloning sites (MCS) at two sides of IRES sequence in pIRES plasmid. Through transduction of the recombinant plasmid to peripheral blood T lymphocytes, a lot of high-efficient cytotoxic T cells for specific recognition of CML related antigen can be obtained, and CML cells can be specifically killed. Simultaneously, TCR mismatching can be reduced and T cellular immunity function can be improved. The recombinant plasmid has high security and has a good application prospect for treating CML. |
| priorityDate | 2012-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.